[go: up one dir, main page]

MX2018012564A - Peptido de la cadena neural para prevenir o reducir el avance de cancer de prostata. - Google Patents

Peptido de la cadena neural para prevenir o reducir el avance de cancer de prostata.

Info

Publication number
MX2018012564A
MX2018012564A MX2018012564A MX2018012564A MX2018012564A MX 2018012564 A MX2018012564 A MX 2018012564A MX 2018012564 A MX2018012564 A MX 2018012564A MX 2018012564 A MX2018012564 A MX 2018012564A MX 2018012564 A MX2018012564 A MX 2018012564A
Authority
MX
Mexico
Prior art keywords
prostate cancer
reducing
progression
preventing
peptide
Prior art date
Application number
MX2018012564A
Other languages
English (en)
Other versions
MX380201B (es
Inventor
Averback Paul
Original Assignee
Nymox Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nymox Corp filed Critical Nymox Corp
Publication of MX2018012564A publication Critical patent/MX2018012564A/es
Publication of MX380201B publication Critical patent/MX380201B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Las modalidades incluyen prevenir o reducir el avance del cáncer de próstata en mamíferos susceptibles de desarrollar cáncer de próstata y reducir la incidencia de cáncer de próstata detectado clínicamente, mediante el uso de composiciones que contienen compuestos basados en péptidos de la cadena neural pequeños en función de la SEQ. ID. NO. 66 (IDQQVLSRIKLEIKRCL) y un portador farmacéuticamente aceptable. La modalidad incluye, de modo no taxativo, administrar los compuestos de forma intramuscular, por vía oral, intravenosa, intraprostática, intratecal, intratumoral, intranasal, tópica, transdérmica, etc., ya sea solo o conjugado con un portador a un mamífero que lo necesita.
MX2018012564A 2016-06-17 2017-06-19 Péptido de la cadena neural para prevenir o reducir el avance de cáncer de próstata. MX380201B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/185,344 US10183058B2 (en) 2016-06-17 2016-06-17 Method of preventing or reducing the progression of prostate cancer
PCT/IB2017/053626 WO2017216779A1 (en) 2016-06-17 2017-06-19 Neural thread peptide for preventing or reducing the progression of prostate cancer

Publications (2)

Publication Number Publication Date
MX2018012564A true MX2018012564A (es) 2019-02-13
MX380201B MX380201B (es) 2025-03-12

Family

ID=59315668

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012564A MX380201B (es) 2016-06-17 2017-06-19 Péptido de la cadena neural para prevenir o reducir el avance de cáncer de próstata.

Country Status (13)

Country Link
US (1) US10183058B2 (es)
EP (1) EP3432907B1 (es)
JP (1) JP6883048B2 (es)
KR (1) KR102169213B1 (es)
CN (2) CN109310732B (es)
AU (1) AU2017283820B2 (es)
BR (1) BR112018071118A2 (es)
CA (1) CA3020252C (es)
MX (1) MX380201B (es)
NZ (1) NZ746758A (es)
RU (1) RU2719598C1 (es)
WO (1) WO2017216779A1 (es)
ZA (1) ZA201806469B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10835538B2 (en) 2018-03-28 2020-11-17 Nymox Corporation Method of treating benign prostatic hyperlasia with antibiotics
US20200061150A1 (en) 2018-08-23 2020-02-27 Nymox Corporation Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function
US11278588B2 (en) 2019-05-13 2022-03-22 Nymox Corporation Method of treating lower urinary tract symptoms with fexapotide triflutate
US20200360466A1 (en) 2019-05-13 2020-11-19 Nymox Corporation Method of improving lower urinary tract symptoms
US11298400B2 (en) 2019-05-13 2022-04-12 Nymox Corporation Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS
US11331374B2 (en) 2019-07-31 2022-05-17 Nymox Corporation Focal treatment of prostate cancer
US11231421B2 (en) 2019-07-31 2022-01-25 Nymox Corporation Methods of treating multifocal cancer
CN120037352B (zh) * 2025-04-23 2025-08-22 广州飞来爱生命科技有限公司 一种脐带间充质干细胞制剂及其在治疗前列腺疾病的用途

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3423507A (en) 1966-02-25 1969-01-21 Schering Corp Method of treating benign prostratic hypertrophy
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4329364A (en) 1974-09-11 1982-05-11 Schering Corporation Antiandrogenic agents and methods for the treatment of androgen dependent disease states
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE2817157A1 (de) 1978-04-17 1979-10-25 Schering Ag Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie
FR2465486A1 (fr) 1979-09-21 1981-03-27 Roussel Uclaf Nouvelle application utilisant la lh-rh ou des agonistes
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3121153A1 (de) 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung von aromatase-hemmern zur prophylaxe und therapie der prostatahyperplasie"
US4457489A (en) 1981-07-13 1984-07-03 Gilmore Samuel E Subsea fluid conduit connections for remote controlled valves
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4659695A (en) 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
US4775660A (en) 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
US4760053A (en) 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
CA1310924C (en) 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
US4970154A (en) 1987-10-09 1990-11-13 Baylor College Of Medicine Method for inserting foreign genes into cells using pulsed radiofrequency
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5948634A (en) 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
ES2094733T3 (es) 1988-12-21 1997-02-01 Gen Hospital Corp Deteccion de enfermedades o disfunciones neurologicas.
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
JPH06256387A (ja) 1991-06-14 1994-09-13 Suetsuna Yoko 新規なペプチド、その製法およびそれを有効成分とする 血圧降下剤
NZ266072A (en) 1993-04-20 1997-07-27 Gen Hospital Corp Neural thread protein and its use in detecting alzheimers, neuroectodermal tumours, malignant astrocytomas and glioblastomas
ATE218893T1 (de) 1993-08-12 2002-06-15 Neurotech Sa Biokompatible immunoisolatorische kapseln, die genetisch veränderte zellen enthalten
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
ZA951877B (en) 1994-03-07 1996-09-09 Dow Chemical Co Bioactive and/or targeted dendrimer conjugates
US5484720A (en) 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection
CA2222550A1 (en) 1995-06-07 1996-12-19 Baylor College Of Medicine Nucleic acid transporters for delivery of nucleic acids into a cell
US6660830B1 (en) 1996-03-26 2003-12-09 Razvan T Radulescu Peptides with antiproliferative properties
US5679559A (en) 1996-07-03 1997-10-21 University Of Utah Research Foundation Cationic polymer and lipoprotein-containing system for gene delivery
CA2282729A1 (en) 1997-02-26 1998-09-03 The General Hospital Corporation Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of alzheimer's disease
WO1999019347A1 (en) 1997-10-10 1999-04-22 Astrazeneca Ab Synthetic genes with immunomodulatory effects
WO2000028004A1 (en) 1998-11-10 2000-05-18 The University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
EP1135494A2 (en) 1998-12-11 2001-09-26 Incyte Pharmaceuticals, Inc. Neuron-associated proteins
WO2000063230A2 (en) 1999-03-26 2000-10-26 Human Genome Sciences, Inc. 49 human secreted proteins
JP2002542766A (ja) 1999-03-12 2002-12-17 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ５０個のヒト分泌タンパク質
AU3628600A (en) 1999-03-19 2000-10-09 Human Genome Sciences, Inc. 46 human secreted proteins
CA2368927A1 (en) 1999-03-26 2000-10-05 Craig A. Rosen 45 human secreted proteins
AU3765500A (en) 1999-03-26 2000-10-16 Human Genome Sciences, Inc. 50 human secreted proteins
CN1300779A (zh) 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽－人神经元线蛋白17和编码这种多肽的多核苷酸
AU2001271455A1 (en) 2000-06-26 2002-01-08 Millennium Pharmaceuticals, Inc. A human calcium channel protein and uses thereof
US7259232B1 (en) 2000-10-27 2007-08-21 Nymox Pharmaceutical Corporation Preferred segments of neural thread protein
CA2325666A1 (fr) 2000-12-01 2002-06-01 Institut Pasteur Peptides immunogeniques mutes derives de r9m, polynucleotides les codants et leurs usages therapeutiques
US6783969B1 (en) 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
DE60222745T2 (de) 2001-03-08 2008-07-10 Nymox Pharmaceutical Corp., St. Laurent Verwendung von neurofilamentproteinen zur behandlung von tumoren
KR20040008177A (ko) 2001-05-16 2004-01-28 니목스 코포레이션 신경 사 단백질 세그먼트를 사용하여 세포 사멸을억제하는 방법
DE60217326T2 (de) 2001-05-25 2007-10-18 Nymox Corp., Saint-Laurent Von neurofilamentproteinen abgeleitete peptide und deren medizinische verwendung
IL159903A0 (en) 2001-07-19 2004-06-20 Nymox Corp Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
US7317077B2 (en) 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
WO2005113720A2 (en) 2004-05-19 2005-12-01 Auburn University A strategy for designing patient-specific anti-cancer drugs
MX2008010942A (es) * 2006-02-28 2008-09-03 Nymox Corp Peptidos efectivos en el tratamiento de tumores y otras condiciones que requieren la remocion o destruccion de celulas.
EA200801942A1 (ru) * 2006-03-10 2009-02-27 Наймокс Корпорейшн Способ предотвращения или уменьшения риска возникновения рака с использованием пептидов на основе белков нервных волокон
US20080027005A1 (en) * 2006-07-31 2008-01-31 Paul Averback Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
US9243035B2 (en) 2013-11-26 2016-01-26 Nymox Corporation Peptides effective in the treatment of conditions requiring the removal or destruction of cells
US9856722B2 (en) 2014-03-14 2018-01-02 General Electric Company Methods and systems for controlling voltage switching
US20160215031A1 (en) 2015-01-27 2016-07-28 Nymox Pharnaceutical Corporation Method of treating disorders requiring destruction or removal of cells
JP6256387B2 (ja) 2015-03-09 2018-01-10 株式会社豊田自動織機 電動圧縮機

Also Published As

Publication number Publication date
EP3432907B1 (en) 2019-10-16
MX380201B (es) 2025-03-12
JP2019523751A (ja) 2019-08-29
US20170360885A1 (en) 2017-12-21
NZ746758A (en) 2022-07-01
WO2017216779A1 (en) 2017-12-21
CA3020252A1 (en) 2017-12-21
CN116785403A (zh) 2023-09-22
JP6883048B2 (ja) 2021-06-02
KR20180124080A (ko) 2018-11-20
BR112018071118A2 (pt) 2019-02-26
CN109310732A (zh) 2019-02-05
CN109310732B (zh) 2023-07-21
ZA201806469B (en) 2020-11-25
AU2017283820A1 (en) 2018-10-18
KR102169213B1 (ko) 2020-10-23
RU2719598C1 (ru) 2020-04-21
CA3020252C (en) 2022-07-26
AU2017283820B2 (en) 2019-09-26
US10183058B2 (en) 2019-01-22
EP3432907A1 (en) 2019-01-30

Similar Documents

Publication Publication Date Title
MX2018012564A (es) Peptido de la cadena neural para prevenir o reducir el avance de cancer de prostata.
NZ751862A (en) Method of ameliorating or preventing the worsening or the progression of symptoms of bph
MX391695B (es) Péptido derivado de una proteína de hebra neural para uso en el tratamiento de desordenes que requieren la destrucción o retiro de células
MA43283B1 (fr) Composition pour le traitement du cancer
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
IL308807B2 (en) Combination therapy for treating cancer
ATE475667T1 (de) Templat-fixierte peptidomimetika
MX2021013163A (es) Métodos para el tratamiento de sujetos con inmunidad preexistente a vectores de transferencia viral.
MX2019010394A (es) Composiciones y metodos para mejorar la funcion sexual.
HK1249011A1 (zh) 包括线粒体分裂抑制肽的治疗组合物、其变体及这些的使用方法
CL2018001407A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
Oikhberg Greedy algorithm with gaps
AR111760A1 (es) Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
NZ750988A (en) Method of preventing or reducing the incidence of acute urinary retention
EP4545072A3 (en) Use of vibegron to treat overactive bladder symptoms in men with benign prostatic hyperplasia
MX2025008168A (es) Métodos de tratamiento de los síntomas del trastorno del espectro autista.
WO2020212514A8 (en) Peptides in combination with immune checkpoint inhibitors for use in treatment of cancer
PH12018501978A1 (en) Pharmaceutical composition comprising pegylated fab fragment of anti-human ngf antibody
WO2019237075A8 (en) Epha2 agonists and uses thereof
WO2014172309A3 (en) Therapeutic compositions for neutralizing type i interferons, and methods of use
WO2018045371A3 (en) nNIF AND nNIF-RELATED PEPTIDES AND RELATED METHODS
MX2021000264A (es) Compuestos peptidicos y usos terapeuticos de los mismos.
WO2017109756A3 (es) Péptidos sintéticos moduladores del receptor nmda
ZA202108521B (en) Method of improving lower urinary tract symptoms
WO2021067611A3 (en) Compositions and methods for treating alzheimer's disease